The FDA FAERS (FDA Adverse Event Reporting System) database receives roughly 2 million adverse event reports per year. For post-market surveillance teams, this is both a goldmine and a minefield. Every report is a potential safety signal — a pattern that could indicate a previously unknown drug-event association, a labeling gap, or the early signature of a class-wide problem. But processing those reports manually, through the six-week batch review cycles that were standard when I joined the team, meant we were always looking in the rearview mirror. By the time a signal was identified, confirmed, and escalated, months had passed.
The manual workflow went like this: safety specialists pulled a monthly extract from FAERS, ran standard disproportionality analyses (PRR, ROR), flagged statistical outliers, read a sample of the underlying reports, and wrote a signal assessment. The six-week cycle was not laziness — it was the time required to do that work carefully with human reviewers. The problem was that emerging signals do not wait for monthly cycles. They accumulate report by report, and the earlier you detect them, the faster you can act.
The NLP Pipeline Architecture
We built a streaming NLP pipeline that processes each FAERS report as it arrives rather than in monthly batches. The core pipeline has three stages. First, named entity recognition extracts drug names (normalized to RxNorm), adverse event terms (mapped to MedDRA), and timing information (onset date, duration, dosing schedule). Second, a temporal relation extraction model identifies which events occurred in which sequence — crucial for distinguishing an adverse event from a pre-existing condition. Third, a signal scoring layer runs disproportionality analysis on a rolling 90-day window, updating scores with each new report and flagging when a drug-event pair crosses the detection threshold.
Medical terminology disambiguation was the hardest engineering problem. The same adverse event can appear in a FAERS report as "MI," "myocardial infarction," "heart attack," "AMI," "acute MI," or a dozen other surface forms — written by a consumer, a nurse, a physician, or a pharmacist, in English, Spanish, or French. We used a combination of dictionary lookup (UMLS), character-level fuzzy matching for misspellings, and a fine-tuned classification model for ambiguous cases. Multi-language reports required a translation step before NLP processing; we used a domain-adapted MT model rather than a generic translation API because clinical terminology translates poorly out of context.
What the System Caught
In the first six months of production operation, the system flagged three drug-event signals that were subsequently confirmed by the safety review committee and escalated to label updates. All three were detected by the real-time system two to four months before they would have appeared in the monthly batch analysis. One involved a rare but serious hepatotoxicity pattern that accumulated slowly — exactly the kind of signal that batch processing misses because no single month shows enough cases to cross the threshold, but the rolling window makes the accumulation visible.
We also caught a significant volume of false positives driven by media contagion effects — a drug mentioned in a news story generates a spike in consumer reports that is not a genuine safety signal. We built a media monitoring integration to flag these spikes and apply a dampening factor to reports filed within 30 days of significant press coverage. This reduced false positive escalations by 40%.
Lessons for Pharma AI Teams
Real-time is not just faster batch. The architecture has to change: you need streaming infrastructure, rolling statistics, and alert fatigue management. The NLP is table stakes; the signal management layer is where most of the product thinking lives. Start with the signal review workflow before you build the detection pipeline — if reviewers cannot efficiently triage and disposition alerts, a more sensitive system just creates more noise. And invest heavily in terminology coverage for your specific drug class: the NLP performance difference between a generic biomedical model and a domain-tuned model is 15-20 F1 points on real FAERS data.
